Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for ...

Studying patients with PD-1 or PD-L1 deficiency may help inform new approaches to fine-tuning immunotherapies to maximise ...

A cancer treatment similar to sac-TMT approved for marketing in China is Trodelvy (sacituzumab govitecan-hziy), developed by ...

Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

Erika P. Hamilton, MD, discusses antibody-drug conjugates in multiple types of breast cancer, and when to use these drugs in ...

Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to ...

The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use ...

Nectin-4 antibody-drug conjugate (ADC) and checkpoint inhibitor combinations have represented a great advancement in the treatment of bladder cancer, but relapse and treatment-related toxicities ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...